- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.09. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer | 82 | GlobeNewswire (Europe) | New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence... ► Artikel lesen | |
| 25.09. | Silexion regains Nasdaq compliance, advances cancer therapy program | 1 | Investing.com | ||
| 25.09. | Silexion Therapeutics Corp: Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements | 92 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 25.09. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data | 5 | Benzinga.com | ||
| 11.09. | Silexion Therapeutics announces pricing of $6M public offering | 3 | Seeking Alpha | ||
| 11.09. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Silexion-Aktie schießt nach positiven Daten zu Krebsmedikament um 400 % in die Höhe | 5 | Investing.com Deutsch | ||
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.09. | Silexion stock soars 400% after positive pancreatic cancer drug data | 2 | Investing.com | ||
| 11.09. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration | 111 | GlobeNewswire (Europe) | New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further Validation... ► Artikel lesen | |
| 05.09. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 04.09. | Silexion beauftragt AMS als CRO-Partner für klinische Studien zur KRAS-Krebstherapie | 1 | Investing.com Deutsch | ||
| 04.09. | Silexion selects CRO partner for upcoming KRAS cancer therapy trials | 2 | Investing.com | ||
| 04.09. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 | 4 | GlobeNewswire (USA) | ||
| 02.09. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 20.08. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.08. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Silexion Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Silexion Therapeutics reports Q2 results | 4 | Seeking Alpha |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,10 | -1,48 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| CUREVAC | 4,656 | -0,17 % | CureVac-Alarm: Insidern zufolge steht eine spektakuläre Trendwende bevor - handeln, bevor es zu spät ist!!! | ||
| AMGEN | 255,70 | +0,91 % | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen | |
| NOVAVAX | 7,363 | -3,85 % | Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU | ||
| BIOGEN | 128,65 | -0,89 % | Erste Patienten bekommen Alzheimer-Mittel Lecanemab der Hersteller Biogen und Eisai | BERLIN (dpa-AFX) - Seit gut einem Monat ist das Alzheimer-Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland verfügbar - inzwischen haben erste Patientinnen und Patienten mit der Therapie... ► Artikel lesen | |
| MAINZ BIOMED | 1,590 | -3,05 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed berichtet Topline-Ergebnisse aus der Machbarkeitsstudie zum Biomarker-Panel im Rahmen seines Bauchspeicheldrüsenkrebs-Projekts | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studienergebnisse
Mainz Biomed berichtet Topline-Ergebnisse aus der Machbarkeitsstudie zum Biomarker-Panel im Rahmen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,160 | +8,35 % | Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero | ||
| INTELLIA THERAPEUTICS | 22,210 | +5,46 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 86,00 | -3,37 % | Tempus AI's $100 Breakout - Billionaire Cliff Asness Reaps 60% Windfall | ||
| BIOCRYST PHARMACEUTICALS | 6,300 | +0,67 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 20,040 | -0,40 % | Sarepta Therapeutics, Inc.: Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress | Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress, taking... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,830 | -0,45 % | 6 Analysts Assess BioMarin Pharmaceutical: What You Need To Know | ||
| EXELIXIS | 33,250 | +0,06 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,914 | -1,19 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,315 | +0,87 % | PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell |
Das Unternehmen SILEXION THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,060 (+1,52 %) liegt der Kurs bei 4,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.